AMSTELVEEN,
(in millions, except per share data)
| Second Quarter | Six Months Ended | ||||||||||
| 2026 | 2025 | 2Q26 | 2Q25 | ||||||||
| $ | 23,900 | $ | 20,998 | $ | 45,508 | $ | 40,524 | ||||
| Adjusted EBITDA (IFRS)¹ ² | $ | 1,429 | $ | 1,754 | $ | 2,563 | $ | 3,281 | |||
| Adjusted EBITDA (USGAAP)¹ ³ | $ | 1,257 | $ | 1,368 | $ | 2,173 | $ | 2,681 | |||
| Adjusted Operating Income (IFRS)¹ ² | $ | 790 | $ | 1,188 | $ | 1,306 | $ | 2,181 | |||
| Adjusted Operating Income (USGAAP)¹ ³ | $ | 866 | $ | 1,034 | $ | 1,410 | $ | 2,033 | |||
| Net Income Attributable to JBS² | $ | -102 | $ | 528 | $ | 118 | $ | 1,028 | |||
| Earnings Per Share Attributable to JBS² | $ | -0.10 | $ | 0.48 | $ | 0.11 | $ | 0.93 | |||
| Adjusted Earnings Per Share Attributable to JBS¹ ² | $ | 0.20 | $ | 0.52 | $ | 0.43 | $ | 1.03 | |||
| Twelve Months Ended | |||||||||||
| 2Q26 | 2Q25 | ||||||||||
| Leverage (Net Debt / Adjusted EBITDA LTM)¹ ² | 3.10x | 2.27x | |||||||||
| Interest Coverage (Adjusted EBITDA LTM / Net Interest Expenses LTM)¹ ² | 5.00x | 7.74x | |||||||||
| ROE LTM ¹ ² | 13.4% | 25.7% | |||||||||
| ROIC LTM ¹ ² | 13.4% | 17.0% | |||||||||
(1) Reconciliations for non-GAAP measures are provided in subsequent sections within this release.
(2) IFRS
(3) USGAAP (non-audited)
Second Quarter Highlights
Net Sales of$23.9 billion , up 14% from prior year- IFRS Adjusted EBITDA of
$1,429 million , down 18% from prior year - USGAAP¹ Adjusted EBITDA of
$1,257 million , down 8% from prior year - IFRS Adjusted operating income of
$790 million , down 34% from prior year - USGAAP¹ Adjusted operating income of
$866 million , down 16% from prior year - EPS of -
$0.10 , vs.$0.48 from prior year - Adjusted EPS of
$0.20 , vs.$0.52 from prior year
“In 2Q26, JBS once again reported a record revenue, reflecting the strength of the Company's multi-geography and multi-protein platform. Compared to last year, profitability was pressured by a tough comparison base, as the poultry operations had posted record results in 2Q25. Compared to the first quarter, profitability already showed an improvement in the majority of our business units.
The quarter recorded a net loss of
Leverage ended 2Q26 at 3.1x, slightly above the Company's long-term target. We also joined the Russell 1000 and Russell 3000 indices, an important milestone that contributes to stock liquidity, expands our shareholder base, and enhances our global visibility. During the quarter, we returned value to our shareholders through a
Pilgrim’s Pride saw firm chicken demand across all regions. In the
JBS Brazil also reported record sales for a second quarter. The revenue growth reflects higher prices and volumes in both the export and domestic markets. In the export market, strong revenue growth was driven by higher prices and volumes, mainly to fill the Chinese quota. Robust global demand and the Company's geographic diversification strategy also boosted exports. In the domestic market, higher prices and volumes for beef were driven by
Seara reported an 18% sales growth compared to the same period of last year, with a strong adjusted EBITDA margin of 14.9% in 2Q26. In the export market, the Company maintained its sales growth driven by higher volumes of fresh poultry. Another highlight was the sales to the
Free Cash Flow & Leverage
Free cash flow in 2Q26 improved by
The average debt term reached 15.3 years, with an average cost of 5.7%. Net leverage ended the quarter at 3.1x, slightly above the company's long-term financial target. In August, JBS increased its revolving credit facility from
SEGMENT RESULTS
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2Q26 | 2Q25 | ||||||||||||||
| $ | 7,770 | $ | 6,805 | 14.2% | $ | 14,936 | $ | 13,227 | 12.9% | ||||||||
| Cost of Sales | $ | (7,661) | $ | (6,826) | 12.2% | $ | (14,890) | $ | (13,149) | 13.2% | |||||||
| Gross Profit | $ | 109 | $ | (21) | - | $ | 46 | $ | 77 | -39.9% | |||||||
| Adjusted EBITDA | $ | (78) | $ | (233) | -66.4% | $ | (345) | $ | (333) | 3.5% | |||||||
| Margin (%) | -1.0% | -3.4% | 2.4 p.p. | -2.3% | -2.5% | 0.2 p.p. | |||||||||||
| Adjusted Operating Income | $ | (138) | $ | (293) | -52.9% | $ | (467) | $ | (451) | 3.5% | |||||||
| Margin (%) | -1.8% | -4.3% | 2.5 p.p. | -3.1% | -3.4% | 0.3 p.p. | |||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2Q26 | 2Q25 | ||||||||||||||
| $ | 7,770 | $ | 6,805 | 14.2% | $ | 14,936 | $ | 13,227 | 12.9% | ||||||||
| Cost of Sales | $ | (7,846) | $ | (7,040) | 11.5% | $ | (15,209) | $ | (13,552) | 12.2% | |||||||
| Gross Profit | $ | (76) | $ | (235) | -67.5% | $ | (273) | $ | (325) | -16.0% | |||||||
| Adjusted EBITDA | $ | (100) | $ | (264) | -62.1% | $ | (330) | $ | (377) | -12.5% | |||||||
| Margin (%) | -1.3% | -3.9% | 2.6 p.p. | -2.2% | -2.9% | 0.7 p.p. | |||||||||||
| Adjusted Operating Income | $ | (148) | $ | (312) | -52.7% | $ | (427) | $ | (471) | -9.2% | |||||||
| Margin (%) | -1.9% | -4.6% | 2.7 p.p. | -2.9% | -3.6% | 0.7 p.p. | |||||||||||
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 4,623 | $ | 4,755 | -2.8% | $ | 9,153 | $ | 9,214 | -0.7% | ||||||||
| Cost of Sales | $ | (4,003) | $ | (3,811) | 5.0% | $ | (7,918) | $ | (7,482) | 5.8% | |||||||
| Gross Profit | $ | 620 | $ | 944 | -34.3% | $ | 1,234 | $ | 1,732 | -28.7% | |||||||
| Adjusted EBITDA | $ | 503 | $ | 818 | -38.5% | $ | 953 | $ | 1,478 | -35.5% | |||||||
| Margin (%) | 10.9% | 17.2% | -6.3 p.p. | 10.4% | 16.0% | -5.6 p.p. | |||||||||||
| Adjusted Operating Income | $ | 240 | $ | 576 | -58.4% | $ | 432 | $ | 1,006 | -57.0% | |||||||
| Margin (%) | 5.2% | 12.1% | -6.9 p.p. | 4.7% | 10.9% | -6.2 p.p. | |||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 4,626 | $ | 4,757 | -2.8% | $ | 9,159 | $ | 9,220 | -0.7% | ||||||||
| Cost of Sales | $ | (4,286) | $ | (4,042) | 6.0% | $ | (8,474) | $ | (7,950) | 6.6% | |||||||
| Gross Profit | $ | 340 | $ | 715 | -52.5% | $ | 685 | $ | 1,270 | -46.1% | |||||||
| Adjusted EBITDA | $ | 360 | $ | 687 | -47.6% | $ | 668 | $ | 1,220 | -45.2% | |||||||
| Margin (%) | 7.8% | 14.4% | -6.6 p.p. | 7.3% | 13.2% | -5.9 p.p. | |||||||||||
| Adjusted Operating Income | $ | 237 | $ | 573 | -58.7% | $ | 426 | $ | 1,002 | -57.5% | |||||||
| Margin (%) | 5.1% | 12.1% | -7.0 p.p. | 4.7% | 10.9% | -6.2 p.p. | |||||||||||
| JBS Brazil | |||||||||||||||||
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 4,585 | $ | 3,581 | 28.0% | $ | 8,373 | $ | 6,751 | 24.0% | ||||||||
| Cost of Sales | $ | (3,959) | $ | (3,032) | 30.6% | $ | (7,232) | $ | (5,733) | 26.1% | |||||||
| Gross Profit | $ | 625 | $ | 549 | 14.0% | $ | 1,142 | $ | 1,018 | 12.2% | |||||||
| Adjusted EBITDA | $ | 269 | $ | 229 | 17.8% | $ | 437 | $ | 360 | 21.5% | |||||||
| Margin (%) | 5.9% | 6.4% | -0.5 p.p. | 5.2% | 5.3% | -0.1 p.p. | |||||||||||
| Adjusted Operating Income | $ | 195 | $ | 174 | 12.5% | $ | 297 | $ | 253 | 17.1% | |||||||
| Margin (%) | 4.3% | 4.8% | -0.5 p.p. | 3.5% | 3.8% | -0.3 p.p. | |||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 4,585 | $ | 3,581 | 28.0% | $ | 8,373 | $ | 6,751 | 24.0% | ||||||||
| Cost of Sales | $ | (4,158) | $ | (3,198) | 30.0% | $ | (7,606) | $ | (6,055) | 25.6% | |||||||
| Gross Profit | $ | 426 | $ | 383 | 11.3% | $ | 767 | $ | 696 | 10.2% | |||||||
| Adjusted EBITDA | $ | 273 | $ | 223 | 22.1% | $ | 445 | $ | 349 | 27.6% | |||||||
| Margin (%) | 5.9% | 6.2% | -0.3 p.p. | 5.3% | 5.2% | 0.1 p.p. | |||||||||||
| Adjusted Operating Income | $ | 200 | $ | 171 | 16.3% | $ | 306 | $ | 249 | 22.8% | |||||||
| Margin (%) | 4.4% | 4.8% | -0.4 p.p. | 3.7% | 3.7% | 0.0 p.p. | |||||||||||
| Seara | |||||||||||||||||
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 2,560 | $ | 2,166 | 18.2% | $ | 4,940 | $ | 4,317 | 14.4% | ||||||||
| Cost of Sales | $ | (1,949) | $ | (1,593) | 22.3% | $ | (3,747) | $ | (3,115) | 20.3% | |||||||
| Gross Profit | $ | 612 | $ | 573 | 6.8% | $ | 1,193 | $ | 1,202 | -0.8% | |||||||
| Adjusted EBITDA | $ | 380 | $ | 392 | -2.9% | $ | 750 | $ | 817 | -8.3% | |||||||
| Margin (%) | 14.9% | 18.1% | -3.2 p.p. | 15.2% | 18.9% | -3.7 p.p. | |||||||||||
| Adjusted Operating Income | $ | 252 | $ | 293 | -14.1% | $ | 500 | $ | 630 | -20.6% | |||||||
| Margin (%) | 9.8% | 13.5% | -3.7 p.p. | 10.1% | 14.6% | -4.5 p.p. | |||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 2,560 | $ | 2,166 | 18.2% | $ | 4,940 | $ | 4,317 | 14.4% | ||||||||
| Cost of Sales | $ | (2,129) | $ | (1,684) | 26.4% | $ | (4,093) | $ | (3,307) | 23.8% | |||||||
| Gross Profit | $ | 431 | $ | 482 | -10.6% | $ | 846 | $ | 1,010 | -16.2% | |||||||
| Adjusted EBITDA | $ | 315 | $ | 334 | -5.8% | $ | 619 | $ | 706 | -12.3% | |||||||
| Margin (%) | 12.3% | 15.4% | -3.1 p.p. | 12.5% | 16.4% | -3.9 p.p. | |||||||||||
| Adjusted Operating Income | $ | 250 | $ | 290 | -13.9% | $ | 496 | $ | 621 | -20.2% | |||||||
| Margin (%) | 9.7% | 13.4% | -3.7 p.p. | 10.0% | 14.4% | -4.4 p.p. | |||||||||||
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 2,565 | $ | 1,973 | 30.0% | $ | 4,710 | $ | 3,594 | 31.0% | ||||||||
| Cost of Sales | $ | (2,232) | $ | (1,571) | 42.0% | $ | (4,133) | $ | (2,942) | 40.4% | |||||||
| Gross Profit | $ | 334 | $ | 401 | -16.9% | $ | 578 | $ | 652 | -11.4% | |||||||
| Adjusted EBITDA | $ | 231 | $ | 290 | -20.5% | $ | 363 | $ | 451 | -19.3% | |||||||
| Margin (%) | 9.0% | 14.7% | -5.7 p.p. | 7.7% | 12.5% | -4.8 p.p. | |||||||||||
| Adjusted Operating Income | $ | 195 | $ | 260 | -24.9% | $ | 294 | $ | 391 | -24.7% | |||||||
| Margin (%) | 7.6% | 13.2% | -5.6 p.p. | 6.2% | 10.9% | -4.7 p.p. | |||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 2,565 | $ | 1,973 | 30.0% | $ | 4,710 | $ | 3,594 | 31.0% | ||||||||
| Cost of Sales | $ | (2,317) | $ | (1,689) | 37.2% | $ | (4,288) | $ | (3,121) | 37.4% | |||||||
| Gross Profit | $ | 249 | $ | 284 | -12.3% | $ | 423 | $ | 473 | -10.7% | |||||||
| Adjusted EBITDA | $ | 218 | $ | 251 | -12.8% | $ | 370 | $ | 419 | -11.7% | |||||||
| Margin (%) | 8.5% | 12.7% | -4.2 p.p. | 7.9% | 11.7% | -3.8 p.p. | |||||||||||
| Adjusted Operating Income | $ | 195 | $ | 231 | -15.8% | $ | 324 | $ | 380 | -14.8% | |||||||
| Margin (%) | 7.6% | 11.7% | -4.1 p.p. | 6.9% | 10.6% | -3.7 p.p. | |||||||||||
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 2,079 | $ | 2,059 | 1.0% | $ | 4,111 | $ | 4,061 | 1.2% | ||||||||
| Cost of Sales | $ | (1,826) | $ | (1,700) | 7.4% | $ | (3,457) | $ | (3,334) | 3.7% | |||||||
| Gross Profit | $ | 254 | $ | 359 | -29.4% | $ | 654 | $ | 727 | -10.1% | |||||||
| Adjusted EBITDA | $ | 117 | $ | 254 | -54.0% | $ | 391 | $ | 501 | -22.0% | |||||||
| Margin (%) | 5.6% | 12.3% | -6.7 p.p. | 9.5% | 12.3% | -2.8 p.p. | |||||||||||
| Adjusted Operating Income | $ | 49 | $ | 185 | -73.2% | $ | 257 | $ | 364 | -29.4% | |||||||
| Margin (%) | 2.4% | 9.0% | -6.6 p.p. | 6.2% | 9.0% | -2.8 p.p. | |||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| $ | 2,079 | $ | 2,059 | 1.0% | $ | 4,111 | $ | 4,061 | 1.2% | ||||||||
| Cost of Sales | $ | (1,883) | $ | (1,916) | -1.7% | $ | (3,700) | $ | (3,687) | 0.3% | |||||||
| Gross Profit | $ | 196 | $ | 143 | 37.6% | $ | 411 | $ | 373 | 10.2% | |||||||
| Adjusted EBITDA | $ | 184 | $ | 134 | 38.0% | $ | 388 | $ | 356 | 8.9% | |||||||
| Margin (%) | 8.9% | 6.5% | 2.4 p.p. | 9.4% | 8.8% | 0.6 p.p. | |||||||||||
| Adjusted Operating Income | $ | 136 | $ | 87 | 56.3% | $ | 292 | $ | 264 | 10.7% | |||||||
| Margin (%) | 6.6% | 4.2% | 2.4 p.p. | 7.1% | 6.5% | 0.6 p.p. | |||||||||||
- USGAAP (non-audited)
| CONSOLIDATED CONDENSED STATEMENTS OF INCOME (In millions, except per share data) (Unaudited) | |||||||||||||
| Second Quarter | Six Months Ended | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| $ | 23,899.6 | $ | 20,997.7 | $ | 45,508.2 | $ | 40,524.2 | ||||||
| Cost of Sales | (21,311.7 | ) | (18,165.1 | ) | (40,595.7 | ) | (35,067.1 | ) | |||||
| Gross Profit | 2,587.9 | 2,832.5 | 4,912.5 | 5,457.1 | |||||||||
| Selling expenses | (1,411.0 | ) | (1,207.0 | ) | (2,713.5 | ) | (2,394.6 | ) | |||||
| General and administrative expenses | (588.1 | ) | (522.3 | ) | (1,143.7 | ) | (1,078.7 | ) | |||||
| Other income(expenses) | 8.3 | 1.9 | 26.4 | 4.3 | |||||||||
| Net Operating Expenses | (1,990.8 | ) | (1,727.4 | ) | (3,830.9 | ) | (3,469.1 | ) | |||||
| Operating Income | 597.1 | 1,105.1 | 1,081.6 | 1,988.0 | |||||||||
| Finance Income | 135.7 | 69.4 | 307.8 | 305.1 | |||||||||
| Finance Expense | (831.2 | ) | (445.8 | ) | (1,317.6 | ) | (873.0 | ) | |||||
| Net Finance Expense | (695.6 | ) | (376.4 | ) | (1,009.8 | ) | (568.0 | ) | |||||
| Share of profit of equity-accounted investees, net of tax | (123.6 | ) | 7.8 | 14.8 | 10.6 | ||||||||
| Profit (Loss) Before Taxes | (222.1 | ) | 736.5 | 86.6 | 1,430.6 | ||||||||
| Current Income Taxes | (18.1 | ) | (165.7 | ) | (51.9 | ) | (390.5 | ) | |||||
| Deferred Income Taxes | 144.0 | 23.5 | 110.7 | 110.5 | |||||||||
| Total Income Taxes | 125.9 | (142.2 | ) | 58.8 | (280.0 | ) | |||||||
| Effective Rate | (56.7 | %) | (19.3 | %) | 67.9 | % | (19.6 | %) | |||||
| Net Income (Loss) | (96.2 | ) | 594.3 | 145.4 | 1,150.6 | ||||||||
| Attributable to: | |||||||||||||
| Company shareholders | (102.1 | ) | 528.1 | 118.5 | 1,028.3 | ||||||||
| Non-controlling interest | 5.9 | 66.2 | 26.9 | 122.3 | |||||||||
| Earnings per Share (US$) | $ | (0.10 | ) | $ | 0.48 | $ | 0.11 | $ | 0.93 | ||||
| IFRS - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Adjusted EBITDA | $ | 1,429.3 | $ | 1,753.6 | -18.5% | $ | 2,562.7 | $ | 3,281.4 | -21.9% | ||||||
| Margin (%) | 6.0% | 8.4% | -2.4 p.p. | 5.6% | 8.1% | -2.5 p.p. | ||||||||||
| Adjusted Operating Income | $ | 790.2 | $ | 1,188.4 | -33.5% | $ | 1,306.1 | $ | 2,180.5 | -40.1% | ||||||
| Margin (%) | 3.3% | 5.7% | -2.4 p.p. | 2.9% | 5.4% | -2.5 p.p. | ||||||||||
| USGAAP¹ - US$ Million | Second Quarter | Var % | Six Months Ended | Var % | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Adjusted EBITDA | $ | 1,256.6 | $ | 1,368.3 | -8.2% | $ | 2,173.1 | $ | 2,680.7 | -18.9% | ||||||
| Margin (%) | 5.3% | 6.5% | -1.2 p.p. | 4.8% | 6.6% | -1.8 p.p. | ||||||||||
| Adjusted Operating Income | $ | 865.9 | $ | 1,034.2 | -16.3% | $ | 1,409.8 | $ | 2,032.8 | -30.6% | ||||||
| Margin (%) | 3.6% | 4.9% | -1.3 p.p. | 3.1% | 5.0% | -1.9 p.p. | ||||||||||
(1) USGAAP (non-audited)
| CONSOLIDATED CONDENSED BALANCE SHEETS (In millions) (Unaudited) | |||||
| Assets | |||||
| Current Assets: | |||||
| Cash and cash equivalents | $ | 3,469.1 | $ | 4,565.1 | |
| Margin Cash | 168.3 | 159.6 | |||
| Trade accounts receivable | 3,555.4 | 4,231.9 | |||
| Inventories | 6,996.2 | 6,107.2 | |||
| Biological assets | 1,810.3 | 1,826.8 | |||
| Recoverable taxes | 1,088.9 | 957.2 | |||
| Derivative assets | 118.2 | 155.6 | |||
| Dividends receivable | - | 1.5 | |||
| Other current assets | 550.4 | 433.4 | |||
| Total Current Assets | 17,756.8 | 18,438.2 | |||
| Non Current Assets: | |||||
| Long-term Investments | 50.9 | 45.8 | |||
| Recoverable taxes | 2,085.7 | 1,874.6 | |||
| Biological assets | 660.1 | 611.8 | |||
| Related party receivables | 32.7 | 41.2 | |||
| Deferred income taxes | 656.1 | 547.0 | |||
| Other non-current assets | 563.9 | 488.8 | |||
| 4,049.4 | 3,609.2 | ||||
| Investments in equity-accounted investees | 225.7 | 171.6 | |||
| Property, plant and equipment | 14,416.0 | 13,645.7 | |||
| Right of use assets | 1,621.8 | 1,613.6 | |||
| Intangible assets | 1,784.8 | 1,825.6 | |||
| 5,983.9 | 5,852.6 | ||||
| Total Non Current Assets | 28,081.6 | 26,718.3 | |||
| Total Assets | $ | 45,838.4 | $ | 45,156.5 | |
| Liabilities and Equity | |||||
| Current Liabilities: | |||||
| Trade accounts payable | $ | 5,851.7 | $ | 6,198.1 | |
| Supply chain finance | 1,195.5 | 1,134.5 | |||
| Loans and financing | 1,334.9 | 833.1 | |||
| Income taxes | 122.9 | 288.0 | |||
| Other taxes payable | 187.6 | 153.0 | |||
| Payroll and social charges | 1,378.3 | 1,560.2 | |||
| Lease liabilities | 368.7 | 354.9 | |||
| Dividends payable | 0.1 | - | |||
| Provisions for legal proceedings | 220.4 | 159.2 | |||
| Derivative liabilities | 116.8 | 156.4 | |||
| Other current liabilities | 805.6 | 704.5 | |||
| Total Current Liabilities | 11,582.6 | 11,541.8 | |||
| Non Current Liabilities: | |||||
| Loans and financings | 21,315.8 | 20,257.5 | |||
| Income and other taxes payable | 424.4 | 407.7 | |||
| Payroll and social charges | 337.8 | 288.1 | |||
| Lease liabilities | 1,425.5 | 1,412.4 | |||
| Deferred income taxes | 1,175.1 | 1,169.3 | |||
| Provisions for legal proceedings | 223.5 | 209.4 | |||
| Related party payable | 142.5 | 191.0 | |||
| Derivative liabilities | 101.9 | 114.4 | |||
| Other non-current liabilities | 50.1 | 42.2 | |||
| Total Non Current Liabilities | 25,196.7 | 24,091.9 | |||
| Equity: | |||||
| Share capital - common shares | 41.6 | 35.1 | |||
| Reserves | 8,064.3 | 6,582.7 | |||
| Undistributed results | 118.5 | 2,085.8 | |||
| Attributable to company shareholders | 8,224.3 | 8,703.6 | |||
| Attributable to non-controlling interest | 834.8 | 819.2 | |||
| Total Equity | 9,059.1 | 9,522.8 | |||
| Total Liabilities and Equity | $ | 45,838.4 | $ | 45,156.5 | |
| CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (In millions) (Unaudited) | ||||||||||||||
| Second Quarter | Six Months Ended | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||
| Net income | $ | (96.2 | ) | $ | 594.3 | 145.4 | 1,150.6 | |||||||
| Adjustments for: | ||||||||||||||
| Depreciation and amortization | 639.1 | 565.2 | 1,256.6 | 1,100.8 | ||||||||||
| Expected credit losses | 2.3 | 0.4 | 5.0 | 13.3 | ||||||||||
| Share of profit of equity-accounted investees | 123.6 | (7.8 | ) | (14.8 | ) | (10.6 | ) | |||||||
| (Gain) loss on assets sales | (0.5 | ) | 1.9 | (13.3 | ) | (8.9 | ) | |||||||
| Taxes expense | (125.9 | ) | 142.2 | (58.8 | ) | 280.0 | ||||||||
| Net finance expense | 695.6 | 376.4 | 1,009.8 | 568.0 | ||||||||||
| Share-based compensation | 19.7 | 7.1 | 25.8 | 14.1 | ||||||||||
| Provisions for legal procedings | 48.2 | 1.5 | 73.0 | 15.6 | ||||||||||
| Impairment of goodwill and property, plant and equipment | 22.6 | 7.4 | 22.6 | 13.6 | ||||||||||
| Net realizable value inventory adjustments | 16.2 | 3.3 | 32.0 | 20.4 | ||||||||||
| Fair value adjustment of biological assets | 96.3 | (95.7 | ) | 71.5 | (86.5 | ) | ||||||||
| Avian Influenza | - | 5.6 | - | 5.6 | ||||||||||
| DOJ ( | 132.7 | 54.1 | 157.4 | 133.6 | ||||||||||
| 1,573.7 | 1,655.9 | 2,712.2 | 3,209.7 | |||||||||||
| Changes in assets and liabilities: | ||||||||||||||
| Trade accounts receivable | 352.5 | (76.8 | ) | 683.6 | 160.1 | |||||||||
| Inventories | (242.2 | ) | (314.3 | ) | (824.6 | ) | (955.2 | ) | ||||||
| Recoverable taxes | (22.1 | ) | 51.7 | (19.5 | ) | 93.8 | ||||||||
| Other current and non-current assets | (96.1 | ) | (73.6 | ) | (88.2 | ) | (362.2 | ) | ||||||
| Biological assets | (232.8 | ) | (206.8 | ) | (415.8 | ) | (398.1 | ) | ||||||
| Trade accounts payable and supply chain finance | 361.6 | (28.0 | ) | (437.7 | ) | (575.4 | ) | |||||||
| Taxes paid in installments | (8.7 | ) | (44.9 | ) | (23.0 | ) | (51.9 | ) | ||||||
| Other current and non-current liabilities | (115.8 | ) | 247.9 | (294.1 | ) | 179.4 | ||||||||
| DOJ and Antitrust agreements payment | (146.1 | ) | (121.5 | ) | (98.8 | ) | (261.2 | ) | ||||||
| Income taxes paid | (181.8 | ) | (316.6 | ) | (400.3 | ) | (550.9 | ) | ||||||
| Changes in operating assets and liabilities | (331.5 | ) | (883.0 | ) | (1,918.5 | ) | (2,721.6 | ) | ||||||
| Cash provided by operating activities | 1,242.2 | 772.9 | 793.7 | 488.1 | ||||||||||
| Interest paid | (444.0 | ) | (293.4 | ) | (810.8 | ) | (604.9 | ) | ||||||
| Interest received | 53.8 | 31.9 | 79.9 | 73.7 | ||||||||||
| Cash net of interest provided by (used in) operating activities | 852.1 | 511.4 | 62.8 | (43.1 | ) | |||||||||
| Cash flow from investing activities: | ||||||||||||||
| Purchases of property, plant and equipment | (612.5 | ) | (449.5 | ) | (1,178.9 | ) | (714.1 | ) | ||||||
| Purchases and disposals of intangible assets | (2.2 | ) | 0.1 | (7.2 | ) | (2.6 | ) | |||||||
| Proceeds from sale of property, plant and equipment | 19.5 | 13.8 | 48.1 | 35.6 | ||||||||||
| Additional/Acquistion investments in equity-accounted investees | (0.0 | ) | (165.3 | ) | 26.4 | (165.3 | ) | |||||||
| Dividends received | 0.2 | 2.2 | 0.2 | 4.1 | ||||||||||
| Related party transactions | (18.5 | ) | 4.6 | (16.8 | ) | 4.6 | ||||||||
| Cash provided by (used in) investing activities | (613.5 | ) | (594.0 | ) | (1,128.2 | ) | (837.6 | ) | ||||||
| Cash flow from financing activities: | ||||||||||||||
| Proceeds from loans and financings | 3,332.5 | 2,313.2 | 3,865.5 | 4,494.2 | ||||||||||
| Payments of loans and financings | (2,265.8 | ) | (2,925.7 | ) | (2,700.7 | ) | (4,676.4 | ) | ||||||
| Derivative instruments received (settled) | 13.7 | (44.0 | ) | (6.5 | ) | (52.9 | ) | |||||||
| Dividends paid | (1,039.1 | ) | (1,194.3 | ) | (1,039.1 | ) | (1,573.9 | ) | ||||||
| Dividends paid to non-controlling interest | (1.1 | ) | (265.5 | ) | (2.9 | ) | (266.4 | ) | ||||||
| Margin Cash | (4.0 | ) | (66.6 | ) | (35.4 | ) | (44.4 | ) | ||||||
| Payments of leasing contracts | (109.8 | ) | (116.8 | ) | (220.8 | ) | (215.1 | ) | ||||||
| Acquisition of treasury shares | - | - | 1.2 | - | ||||||||||
| Others | - | - | (2.8 | ) | - | |||||||||
| Cash provided by (used in) financing activities | (73.7 | ) | (2,299.8 | ) | (141.4 | ) | (2,334.8 | ) | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 9.4 | 75.2 | 110.8 | 120.5 | ||||||||||
| Net change in cash and cash equivalents | 174.3 | (2,307.2 | ) | (1,096.0 | ) | (3,094.9 | ) | |||||||
| Cash and cash equivalents at the beggining of period | 3,294.8 | 4,826.0 | 4,565.1 | 5,613.7 | ||||||||||
| Cash and cash equivalents at the end of period | $ | 3,469.1 | $ | 2,518.8 | $ | 3,469.1 | $ | 2,518.8 | ||||||
| Adjusted EBITDA IFRS to USGAAP Reconciliations (In millions) (Unaudited) | ||||||||||||||||||||||||
| Adjusted EBITDA 2Q26 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted EBITDA IFRS | $ | (78.3 | ) | $ | 502.9 | $ | 269.2 | $ | 380.4 | $ | 116.7 | $ | 230.7 | $ | 7.6 | $ | 1,429.3 | |||||||
| Leasing adjustments | (14.4 | ) | (20.5 | ) | (2.9 | ) | (10.8 | ) | (22.4 | ) | (14.4 | ) | (0.5 | ) | (85.9 | ) | ||||||||
| Inventory adjustments at market value | (7.4 | ) | - | - | - | (11.1 | ) | - | - | (18.6 | ) | |||||||||||||
| Biological assets adjustments | - | (123.1 | ) | 6.4 | (55.1 | ) | 101.1 | 2.1 | - | (68.6 | ) | |||||||||||||
| Other adjustments | (0.1 | ) | 0.7 | - | - | - | - | (0.3 | ) | 0.3 | ||||||||||||||
| Adjusted EBITDA USGAAP¹ | $ | (100.3 | ) | $ | 360.0 | $ | 272.8 | $ | 314.5 | $ | 184.3 | $ | 218.5 | $ | 6.8 | $ | 1,256.6 | |||||||
| Adjusted EBITDA 2Q25 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted EBITDA IFRS | $ | (233.0 | ) | $ | 817.7 | $ | 228.6 | $ | 391.8 | $ | 253.6 | $ | 290.2 | $ | 4.7 | $ | 1,753.6 | |||||||
| Leasing adjustments | (14.4 | ) | (19.8 | ) | (3.5 | ) | (13.8 | ) | (26.3 | ) | (13.0 | ) | (0.6 | ) | (91.4 | ) | ||||||||
| Inventory adjustments at market value | (16.9 | ) | - | - | - | (29.8 | ) | - | - | (46.7 | ) | |||||||||||||
| Biological assets adjustments | - | (111.2 | ) | (1.6 | ) | (44.2 | ) | (63.9 | ) | (26.7 | ) | - | (247.6 | ) | ||||||||||
| Other adjustments | (0.1 | ) | 0.1 | - | - | - | - | 0.4 | 0.5 | |||||||||||||||
| Adjusted EBITDA USGAAP¹ | $ | (264.4 | ) | 686.9 | $ | 223.5 | $ | 333.8 | $ | 133.6 | $ | 250.5 | $ | 4.5 | $ | 1,368.3 | ||||||||
| Adjusted EBITDA 6M26 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted EBITDA IFRS | $ | (345.0 | ) | $ | 952.6 | $ | 436.9 | $ | 749.7 | $ | 390.8 | $ | 363.5 | $ | 14.2 | $ | 2,562.7 | |||||||
| Leasing adjustments | (29.3 | ) | (42.3 | ) | (7.0 | ) | (22.3 | ) | (44.2 | ) | (28.2 | ) | (1.0 | ) | (174.4 | ) | ||||||||
| Inventory adjustments at market value | 44.6 | - | - | - | (10.5 | ) | - | - | 34.0 | |||||||||||||||
| Biological assets adjustments | - | (243.2 | ) | 14.9 | (108.5 | ) | 52.0 | 35.1 | - | (249.7 | ) | |||||||||||||
| Other adjustments | (0.3 | ) | 1.1 | - | - | - | - | (0.3 | ) | 0.5 | ||||||||||||||
| Adjusted EBITDA USGAAP¹ | $ | (330.2 | ) | 668.1 | $ | 444.8 | $ | 618.9 | $ | 388.1 | $ | 370.4 | $ | 12.8 | $ | 2,173.1 | ||||||||
| Adjusted EBITDA 6M25 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted EBITDA IFRS | $ | (333.5 | ) | $ | 1,477.9 | $ | 359.7 | $ | 817.5 | $ | 500.9 | $ | 450.5 | $ | 8.3 | $ | 3,281.4 | |||||||
| Leasing adjustments | (29.2 | ) | (39.5 | ) | (7.9 | ) | (29.5 | ) | (51.7 | ) | (25.2 | ) | (1.3 | ) | (184.4 | ) | ||||||||
| Inventory adjustments at market value | (14.6 | ) | - | - | - | (23.8 | ) | - | - | (38.5 | ) | |||||||||||||
| Biological assets adjustments | - | (218.9 | ) | (3.1 | ) | (82.1 | ) | (69.1 | ) | (6.0 | ) | - | (379.1 | ) | ||||||||||
| Other adjustments | (0.0 | ) | 0.6 | - | - | - | - | 0.8 | 1.3 | |||||||||||||||
| Adjusted EBITDA USGAAP¹ | $ | (377.3 | ) | $ | 1,220.1 | $ | 348.6 | $ | 705.9 | $ | 356.3 | $ | 419.4 | $ | 7.7 | $ | 2,680.8 | |||||||
(1) USGAAP (non-audited)
| Adjusted Operating Income IFRS to USGAAP Reconciliations (In millions) (Unaudited) | ||||||||||||||||||||||||
| Adjusted Operating Income (Loss) 2Q26 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted Operating Income IFRS | $ | (138.1 | ) | $ | 239.7 | $ | 195.3 | $ | 251.7 | $ | 49.5 | $ | 195.3 | $ | (3.2 | ) | $ | 790.2 | ||||||
| Leasing adjustments | (2.5 | ) | (3.2 | ) | (2.6 | ) | (2.1 | ) | (3.1 | ) | (2.9 | ) | (0.0 | ) | (16.5 | ) | ||||||||
| Inventory adjustments at market value | (7.4 | ) | - | - | - | (11.1 | ) | - | - | (18.6 | ) | |||||||||||||
| Biological assets adjustments | - | - | 6.9 | - | 101.1 | 2.1 | - | 110.1 | ||||||||||||||||
| Other adjustments | 0.2 | 0.2 | - | - | - | - | 0.2 | 0.6 | ||||||||||||||||
| Adjusted Operating Income USGAAP¹ | $ | (147.9 | ) | $ | 236.7 | $ | 199.5 | $ | 249.6 | $ | 136.3 | $ | 194.6 | $ | (3.0 | ) | $ | 865.9 | ||||||
| Adjusted Operating Income (Loss) 2Q25 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted Operating Income IFRS | $ | (292.9 | ) | $ | 575.8 | $ | 173.6 | $ | 293.2 | $ | 184.7 | $ | 260.1 | $ | (6.2 | ) | $ | 1,188.4 | ||||||
| Leasing adjustments | (2.6 | ) | (3.1 | ) | (0.5 | ) | (3.4 | ) | (3.8 | ) | (2.4 | ) | (0.0 | ) | (15.9 | ) | ||||||||
| Inventory adjustments at market value | (16.9 | ) | - | - | - | (29.8 | ) | - | - | (46.7 | ) | |||||||||||||
| Biological assets adjustments | - | - | (1.6 | ) | - | (63.9 | ) | (26.7 | ) | - | (92.3 | ) | ||||||||||||
| Other adjustments | 0.1 | 0.6 | - | - | - | - | (0.0 | ) | 0.7 | |||||||||||||||
| Adjusted Operating Income USGAAP¹ | $ | (312.3 | ) | $ | 573.4 | $ | 171.5 | $ | 289.8 | $ | 87.2 | $ | 230.9 | $ | (6.2 | ) | $ | 1,034.2 | ||||||
| Adjusted Operating Income (Loss) 6M26 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted Operating Income IFRS | $ | (466.9 | ) | $ | 432.5 | $ | 296.6 | $ | 500.1 | $ | 256.7 | $ | 294.2 | $ | (7.1 | ) | $ | 1,306.1 | ||||||
| Leasing adjustments | (5.1 | ) | (6.5 | ) | (6.2 | ) | (4.3 | ) | (6.2 | ) | (5.5 | ) | (0.1 | ) | (33.9 | ) | ||||||||
| Inventory adjustments at market value | 44.6 | - | - | - | (10.5 | ) | - | - | 34.0 | |||||||||||||||
| Biological assets adjustments | - | - | 15.5 | - | 52.0 | 35.1 | - | 102.6 | ||||||||||||||||
| Other adjustments | 0.2 | 0.3 | - | - | - | - | $ | 0.5 | 1.0 | |||||||||||||||
| Adjusted Operating Income USGAAP¹ | $ | (427.2 | ) | $ | 426.3 | $ | 305.9 | $ | 495.8 | $ | 292.0 | $ | 323.8 | $ | (6.7 | ) | $ | 1,409.8 | ||||||
| Adjusted Operating Income (Loss) 6M25 | ||||||||||||||||||||||||
| JBS Beef North America | PPC | JBS Brazil | Seara | Pork | Miscellaneous | Total | ||||||||||||||||||
| Adjusted Operating Income IFRS | $ | (451.2 | ) | $ | 1,006.5 | $ | 253.2 | $ | 629.8 | $ | 363.8 | $ | 390.7 | $ | (12.4 | ) | $ | 2,180.5 | ||||||
| Leasing adjustments | (5.4 | ) | (5.9 | ) | (1.0 | ) | (8.7 | ) | (7.1 | ) | (4.8 | ) | (0.0 | ) | (32.9 | ) | ||||||||
| Inventory adjustments at market value | (14.6 | ) | - | - | - | (23.8 | ) | - | - | (38.5 | ) | |||||||||||||
| Biological assets adjustments | - | - | (3.1 | ) | - | (69.1 | ) | (6.0 | ) | - | (78.1 | ) | ||||||||||||
| Other adjustments | 0.5 | 1.5 | - | - | - | - | (0.2 | ) | 1.8 | |||||||||||||||
| Adjusted Operating Income USGAAP¹ | $ | (470.7 | ) | 1,002.1 | $ | 249.1 | $ | 621.1 | $ | 263.8 | $ | 379.9 | $ | (12.6 | ) | $ | 2,032.8 | |||||||
(1) USGAAP (non-audited)
| EBITDA to Adjusted EBITDA and Free Cash Flow Reconciliation (In millions) | |||||||||||||
| Second Quarter | Twelve Months Ended | ||||||||||||
| 2026 | 2025 | 2Q26 | 2Q25 | ||||||||||
| Profit before Taxes | $ | (222.1 | ) | $ | 736.5 | $ | 1,276.3 | $ | 3,237.0 | ||||
| Share of profit of equity-accounted investees, net of tax | 123.6 | (7.8 | ) | (21.1 | ) | (17.6 | ) | ||||||
| Net finance results | 695.6 | 376.4 | 1,998.1 | 1,289.4 | |||||||||
| (+) Depreciation and amortization | 639.1 | 565.2 | 2,464.3 | 2,199.6 | |||||||||
| EBITDA | $ | 1,236.2 | $ | 1,670.3 | $ | 5,717.6 | $ | 6,708.3 | |||||
| Adjustments to EBITDA: | |||||||||||||
| Other operating income (expense), net | $ | 9.3 | $ | 9.0 | $ | 38.4 | $ | 38.2 | |||||
| Tax Assesment Notice | - | - | 43.2 | - | |||||||||
| Reestructuring | 17.3 | 4.5 | 32.0 | 64.9 | |||||||||
| Impairment of assets | - | 7.1 | 8.4 | 12.8 | |||||||||
| Antitrust agreements | 132.7 | 54.1 | 206.0 | 307.1 | |||||||||
| Donations and Social Programs | - | 0.6 | 1.2 | 9.0 | |||||||||
| Rio | - | - | - | 13.1 | |||||||||
| Fiscal payments and installments | 9.6 | 2.4 | 9.6 | 2.4 | |||||||||
| Extemporaneous litigation | - | - | 20.7 | 61.0 | |||||||||
| Reversal of tax credits | - | - | - | 58.7 | |||||||||
| Avian influenza | - | 5.6 | 11.5 | 5.6 | |||||||||
| Closure of Plants | 24.1 | - | 24.1 | - | |||||||||
| Total Adjusted EBITDA | $ | 1,429.3 | $ | 1,753.6 | $ | 6,112.7 | $ | 7,281.0 | |||||
| (-) Depreciation and amortization | 639.1 | 565.2 | 2,464.3 | 2,199.6 | |||||||||
| Adjusted Operating Income (IFRS) | $ | 790.2 | $ | 1,188.4 | $ | 3,648.5 | $ | 5,081.4 | |||||
| Total Gross Debt | 22,650.7 | 19,491.8 | 22,650.7 | 19,491.8 | |||||||||
| (-) Cash and Equivalents | 3,469.1 | 2,518.8 | 3,469.1 | 2,518.8 | |||||||||
| (-) Cash Margin | 168.3 | 449.2 | 168.3 | 449.2 | |||||||||
| (-) Financial Investments | 50.9 | - | 50.9 | - | |||||||||
| Total Net Debt | $ | 18,962.3 | $ | 16,523.8 | $ | 18,962.3 | $ | 16,523.8 | |||||
| Ratio Calculations: | |||||||||||||
| Gross Debt/Adjusted EBITDA | 3.71x | 2.68x | |||||||||||
| Net Debt/Adjusted EBITDA | 3.10x | 2.27x | |||||||||||
| Second Quarter | Twelve Months Ended | ||||||||||||
| 2026 | 2025 | 2Q26 | 2Q25 | ||||||||||
| Cash provided by operating activities | $ | 1,242.2 | $ | 772.9 | $ | 4,352.2 | $ | 4,147.7 | |||||
| Interest paid and received | (390.2 | ) | (261.5 | ) | (1,313.5 | ) | (1,233.7 | ) | |||||
| Purchases of property, plant and equipment | (612.5 | ) | (449.5 | ) | (2,564.0 | ) | (1,564.7 | ) | |||||
| Payments of leasing contracts | (109.8 | ) | (116.8 | ) | (438.3 | ) | (421.8 | ) | |||||
| Free Cash Flow | $ | 129.7 | $ | (54.9 | ) | $ | 36.4 | $ | 927.5 | ||||
(In millions)
(Unaudited)


| Adjusted Net Income Reconciliation (In millions) (Unaudited) | |||||||||||||
| Second Quarter | Six Months Ended | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| Net Income (Loss) | $ | (96.2 | ) | $ | 594.3 | $ | 145.4 | $ | 1,150.6 | ||||
| Non-controlling interest | (5.9 | ) | (66.2 | ) | (26.9 | ) | (122.3 | ) | |||||
| Net income (Loss) Attributable to JBS | $ | (102.1 | ) | $ | 528.1 | $ | 118.5 | $ | 1,028.3 | ||||
| Adjustments to Net Income: | |||||||||||||
| Other operating income / expense | $ | 9.3 | $ | 9.0 | $ | 12.7 | $ | 15.4 | |||||
| Reestructuring | 17.3 | 4.5 | 20.1 | 21.5 | |||||||||
| Antitrust agreements | 132.7 | 54.1 | 157.4 | 133.6 | |||||||||
| Donations and Social Programs | - | 0.6 | 0.5 | 1.1 | |||||||||
| Avian influenza | - | 5.6 | - | 5.6 | |||||||||
| Fiscal payments and installments | 9.6 | 2.4 | 9.6 | 2.4 | |||||||||
| Closure of Plants | 24.1 | - | 24.1 | - | |||||||||
| Final calculation of the bargain purchase price gain | 80.5 | - | 80.5 | - | |||||||||
| Bond and CRA premiums | 172.1 | - | 172.1 | - | |||||||||
| Costs Related to the War | 39.8 | - | 39.8 | - | |||||||||
| Taxes | (165.1 | ) | (25.9 | ) | (175.7 | ) | (61.1 | ) | |||||
| Adjusted Net income Attributable to JBS | $ | 218.3 | $ | 578.4 | $ | 459.6 | $ | 1,146.9 | |||||
| Adjusted Earnings Per Share Attributable to JBS | $ | 0.20 | $ | 0.52 | $ | 0.43 | $ | 1.03 | |||||
| ROE, ROIC and Interest Coverage Reconciliation (In millions) (Unaudited) | ||||||
| Last twelve months ended | ||||||
| 2026 | 2025 | |||||
| Net Income LTM (A) | $ | 1,224.6 | $ | 2,365.6 | ||
| Average Shareholder Equity (B) | $ | 9,152.7 | $ | 9,190.9 | ||
| Current Shareholder Equity | $ | 9,059.1 | $ | 9,246.4 | ||
| Previous Year Shareholder Equity | $ | 9,246.4 | $ | 9,135.5 | ||
| ROE (A/B) | 13.4% | 25.7% | ||||
| Last twelve months ended | ||||||
| 2026 | 2025 | |||||
| NOPAT (A) | $ | 3,596.7 | $ | 4,210.1 | ||
| Adjusted Operating Income (IFRS) | $ | 3,648.5 | $ | 5,081.4 | ||
| Taxes | $ | -51.7 | $ | -871.4 | ||
| Average Net Debt (B) | $ | 17,743.1 | $ | 15,641.6 | ||
| Current Net Debt | $ | 18,962.3 | $ | 16,523.8 | ||
| Previous Year | $ | 16,523.8 | $ | 14,759.4 | ||
| Average Shareholder Equity (C) | $ | 9,152.7 | $ | 9,190.9 | ||
| Current Shareholder Equity | $ | 9,059.1 | $ | 9,246.4 | ||
| Previous Year Shareholder Equity | $ | 9,246.4 | $ | 9,135.5 | ||
| $ | 26,895.8 | $ | 24,832.6 | |||
| ROIC [A/(B+C)] | 13.4% | 17.0% | ||||
| Last twelve months ended | ||||||
| 2026 | 2025 | |||||
| Total Adjusted EBITDA | $ | 6,112.7 | $ | 7,281.0 | ||
| Net Financial Expense | $ | 1,222.5 | $ | 941.1 | ||
| Interest Coverage | 5.00x | 7.74x | ||||
Conference Call Information and Other Selected Data
JBS will host a conference call to discuss its financial results on
This press release is being made in respect of
Forward-Looking Statements
We make statements about future events that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our Management and information to which the Company currently has access. Statements about future events include information about our current intentions, beliefs or expectations, as well as those of the members of the Company's Board of Directors and Officers.
Forward-looking statements may include information on possible or presumed operating results, as well as statements that are preceded, followed or that include the words "believe,“ "may," "will," "continue," “expects,“ "predicts," "intends," "plans," "estimates," or similar expressions.
Forward-looking statements and information are not guarantees of performance. They involve risks, uncertainties and assumptions because they refer to future events, depending, therefore, on circumstances that may or may not occur. Future results and shareholder value creation may differ materially from those expressed or implied by the forward-looking statements. Many of the factors that will determine these results and values are beyond our ability to control or predict.
IFRS and Non-GAAP Financial Measures
This release is prepared under IFRS and also includes certain non-GAAP financial measures. These measures are not calculated in accordance with any generally accepted accounting principles (GAAP) or International Financial Reporting Standards (IFRS) and should not be viewed as substitutes for IFRS metrics such as net income, operating cash flow, or other measures of operating performance or liquidity.
We present non-GAAP financial measures to provide additional information that we believe is useful and meaningful to investors. However, such measures do not have standardized definitions and may therefore not be comparable to similarly titled measures presented by other companies. Non-GAAP financial measures should always be considered together with, and not as alternatives to, the financial results reported in accordance with IFRS as issued by the International Accounting Standards Board.
Additionally, all the numbers are unaudited in the condensed consolidated interim financial information, the consolidated US GAAP figure includes non-audited accounting GAAP adjustments in Seara and JBS Brazil, in addition to the Business Units that already report under US GAAP.
Investor Contact: ir@jbsglobal.com
Guilherme Cavalcanti (Global CFO)
Christiane Assis (IRO)
Pedro Bueno
Felipe Brindo
Vítor Figueira
Amanda Harumi
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/5d7a7830-cc4c-4e73-9a61-e6296777ef75
https://www.globenewswire.com/NewsRoom/AttachmentNg/40a189ff-1017-4107-a2f9-0d4f0e7c3f00
Source: JBS N.V.
